Valuation: Myriad Genetics, Inc.

Market Cap 290M 250M 235M 214M 402M 27.71B 409M 2.76B 1.08B 13.88B 1.09B 1.06B 46.12B P/E 2026 *
-1.94x
P/E 2027 * -2.55x
Enterprise Value 290M 250M 235M 214M 402M 27.71B 409M 2.76B 1.08B 13.88B 1.09B 1.06B 46.12B EV / Sales 2026 *
0.37x
EV / Sales 2027 * 0.35x
Free-Float
96.02%
Yield 2026 *
-
Yield 2027 * -
1 day-4.42%
1 week-7.06%
Current month+5.94%
1 month-51.05%
3 months-15.36%
6 months-32.52%
Current year-50.73%
1 week 3.01
Extreme 3.01
3.28
1 month 2.74
Extreme 2.74
6.19
Current year 2.74
Extreme 2.74
7.15
1 year 2.74
Extreme 2.74
8.59
3 years 2.74
Extreme 2.74
29.3
5 years 2.74
Extreme 2.74
36.95
10 years 2.74
Extreme 2.74
50.44
Manager TitleAgeSince
Chief Executive Officer 54 29/04/2025
Director of Finance/CFO 43 15/08/2025
Chief Tech/Sci/R&D Officer - 31/05/2026
Director TitleAgeSince
Chairman 67 22/03/2020
Director/Board Member 71 09/06/2010
Director/Board Member 66 24/09/2019
Date Insider Type Main position Quantity % Market Cap.
11/06/26 Free

Chief Executive Officer

3,542 0.0038%
22/03/26 Tax

Chief Operating Officer

2,055 0.0022%
01/03/26 Tax

Head of Human Resources

1,675 0.0018%
Change 5-day change 1-year change 3-year change Capi.($)
-4.42%-7.06%-46.94%-82.06% 290M
-1.46%-6.69%+167.00%+347.13% 21.1B
+0.14%+0.34%-41.94%-21.36% 9.96B
-3.54%+7.80%+319.84%+17.15% 7.31B
+0.01%0.00%+86.32%+51.28% 6.59B
-1.71%-4.13%-40.27% - 6.16B
+3.22%+6.11%-12.93%-8.79% 5.97B
+1.19%+0.81%+81.12%+106.81% 4.55B
0.00%-1.30%-11.45%-17.57% 4.27B
+3.92%+3.82%-19.12%-32.51% 2.85B
Average -0.26%+2.56%+48.16%+40.01% 6.9B
Weighted average by Cap. -0.45%+1.16%+86.01%+124.29%

Financials

2026 *2027 *
Net sales 778M 672M 631M 574M 1.08B 74.4B 1.1B 7.4B 2.89B 37.26B 2.92B 2.86B 124B 822M 710M 667M 607M 1.14B 78.62B 1.16B 7.82B 3.06B 39.37B 3.09B 3.02B 131B
Net income -148M -128M -120M -109M -206M -14.18B -209M -1.41B -551M -7.1B -557M -545M -23.6B -115M -99.69M -93.68M -85.2M -160M -11.04B -163M -1.1B -429M -5.53B -433M -424M -18.37B
Net Debt - -
Logo Myriad Genetics, Inc.
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
Employees
2,700
Date Price Change Volume
14/08/26 US$3.030 -4.42% 1,555,214
13/08/26 US$3.170 -1.86% 1,619,917
12/08/26 US$3.230 +0.31% 1,162,680
11/08/26 US$3.220 -0.92% 1,485,433
10/08/26 US$3.250 -0.31% 1,376,930
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
3.030USD
Average target price
4.093USD
Spread / Average Target
+35.08%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MYGN Stock